DirectorsTalk Interviews

DirectorsTalk

DirectorsTalk Interviews focus on financial markets and investment opportunities. The site features interviews with company directors, market analysts, and experts, offering insights into companies' performance, industry trends, and market updates. The content includes Q&A sessions, market commentary, and discussions about business developments, often highlighting the viewpoints of executives from publicly traded companies.

  1. vor 1 Tag

    Corero Network Security: $11.1m Order Surge, Tier-1 Telecoms Wins and AI Cybersecurity Growth Opportunity

    Carl Herberger, Chief Executive Officer of Corero Network Security plc (LON:CNS), explains what's driving a 50% surge in third-quarter order intake to $11.1 million, including two major Tier-1 telecommunications contracts worth a combined $4.8 million in the UK and US. With a $3.4 million five-year managed services agreement demonstrating Corero's ability to compete for critical infrastructure contracts, Herberger discusses how stronger technology, strategic partnerships and international expansion are opening doors to larger customers. He also reveals why AI is creating opportunities on both sides of the cybersecurity market, as increasingly sophisticated attacks drive demand for automated protection while the rapid growth of AI data centres adds another layer of network security requirements. With new products, further partnerships and additional customer wins on the horizon, Herberger outlines why 2027 could mark an important step forward for Corero's global ambitions. Key Moments 00:00 - Carl Herberger introduces Corero's Q3 update 00:16 - Order intake jumps 50% to $11.1m 00:35 - Two major Tier-1 telecoms contract wins 00:50 - $3.4m UK telecoms deal secured over five years 01:34 - $1.4m US contract highlights software capabilities 02:10 - Why Tier-1 wins could unlock larger opportunities 03:01 - Engineering performance drives competitive advantage 03:55 - International expansion and leadership investment 04:07 - Targeting the $4bn to $5bn cyber resilience market 04:53 - Michael Woduschegg strengthens international growth plans 05:45 - AI attacks accelerate demand for DDoS protection 06:48 - Fighting AI-powered attacks with automated defences 08:00 - AI data centres create another growth opportunity 09:03 - Corero's priorities for 2027 09:29 - New products and channel partnerships to drive expansion 10:10 - More customer wins and deeper market penetration

    Corero Network Security: $11.1m Order Surge, Tier-1 Telecoms Wins and AI Cybersecurity Growth Opportunity
  2. vor 4 Tagen

    Manx Financial Group: £313m Structured Finance Portfolio, New Lending Launch and AI-Driven Growth Plans

    Douglas Grant, Group Chief Executive Officer of Manx Financial Group plc (LON:MFX), outlines how the Group is positioning itself for stronger growth in 2027 and 2028 following a third quarter that saw net interest income climb 9.6% to £10.3 million. With Conister Bank’s structured finance facilities exceeding £313 million, a lending pipeline above £100 million and the Conister Halo overdraft product targeting launch in early 2027, several significant opportunities are taking shape. Grant also discusses the £1 million profit improvement targeted through Triskel Finance, Payment Assist’s potential minority IPO following its 2028 results, expansion opportunities in Ireland and across Europe, and an AI programme already reducing costs and accelerating product development. With several milestones approaching, he explains where investors could see the next stage of value creation. Key Moments: 00:00 Douglas Grant joins us for the Q3 update 00:13 Q3 progress sets the stage for 2027 and 2028 00:58 £10.3m net interest income and lending demand 02:47 Conister Halo targets a Q1 2027 launch 04:22 £313m structured finance facilities and £100m-plus pipeline 05:52 Triskel Finance targets £1m profit improvement 06:59 Payment Assist growth and potential minority IPO 08:12 Irish licence could open up European markets 08:58 AI cuts costs and accelerates development 10:45 A new AI-developed system approaches announcement

    Manx Financial Group: £313m Structured Finance Portfolio, New Lending Launch and AI-Driven Growth Plans
  3. vor 6 Tagen

    Gattaca Profits Surge 85% as Contract Growth Fuels Momentum into FY27

    Gattaca plc (LON:GATC) has reported an 85% increase in underlying profit before tax to £6.1 million, supported by 11% net fee income growth and a 20% improvement in NFI per sales head. In our latest interview, CEO Matthew Wragg explains how four years of strategic focus are translating into stronger financial performance. Key themes include 16% growth in contract recruitment, expanding opportunities in defence and digital technology, the integration of InfoSec People and the Group's ability to pursue further market share gains. With over £15 million in cash and renewed momentum heading into FY27, the conversation explores the next stage of Gattaca's growth strategy. Watch the full interview. More Info: https://www.directorstalkinterviews.com/gattaca-profits-surge-85-as-contract-growth-fuels-momentum-into-fy27-video/4121269051 Key Moments 00:00 Introduction to Matthew Wragg and FY26 results00:20 Profits jump 85% as NFI hits £43.2m00:40 Contract growth, cash strength and doubled dividend01:03 Staff engagement and InfoSec People acquisition01:45 The decisions powering Gattaca’s turnaround02:03 Contractor numbers rise over 10%02:17 Sales productivity surges 20%02:52 Defence grows 17% despite tough markets03:11 Digital technology delivers double-digit growth03:23 Infrastructure, energy and cyber security progress03:49 Statement of Work faces challenges04:16 Four strategic priorities driving growth04:49 Matchtech brand consolidation05:24 Culture and staff engagement strengthen06:00 Operational efficiency boosts profit conversion06:38 FY27 outlook and investment case07:33 78% contract visibility supports planning07:52 Further growth and bolt-on acquisitions08:17 Market share opportunity amid industry weaknessMore CEO Interviews: https://www.directorstalkinterviews.com/exclusives #Gattaca #GATC #Recruitment #Engineering #Leadership #Investing

    Gattaca Profits Surge 85% as Contract Growth Fuels Momentum into FY27
  4. 27. Okt.

    ICG Enterprise Trust: 16% Earnings Growth, 24 Exits and the AI Opportunity Behind Its Defensive Strategy

    ICG Enterprise Trust: Strong portfolio growth and the potential for a recovery in private equity exits. With EBITDA growth of 16%, revenue growth of 11% and 24 exits at an average three times cost, ICG Enterprise Trust's latest results provide evidence of its underlying portfolio performance. In this interview, Hardman & Co analyst Mark Thomas explores the factors supporting that growth, the availability of private equity capital, AI-driven operational efficiencies and the prospects for further realisations. He also examines portfolio valuations, NAV discounts and why ICGT's approach has historically delivered sector-level returns with below-sector risk. Watch the interview for a closer look at the opportunities and challenges facing ICGT. Key Moments 00:07 – Why the research report carries an investor disclaimer 00:44 – Key findings from the first-half 2027 results 01:47 – 16% EBITDA growth, 24 exits and attractive exit uplifts 02:39 – What drives ICGT's consistent portfolio growth 03:56 – Why selecting the right private equity managers matters 04:22 – The outlook for exits and future realisations 05:11 – How AI could improve private equity returns 05:55 – Portfolio maturity, valuations and balance sheet strength 06:43 – Delivering sector-level returns with lower risk 07:07 – NAV discounts, interest rates and investment risks #ICGEnterpriseTrust #ICGT #PrivateEquity #InvestmentTrusts #AssetManagement

    ICG Enterprise Trust: 16% Earnings Growth, 24 Exits and the AI Opportunity Behind Its Defensive Strategy
  5. 8. Okt.

    Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus

    Genflow Biosciences (LON:GENF / OTCQB:GENFF) has reported encouraging interim results from its SLAB-VET-001 study, giving investors an early look at how its centenarian-derived SIRT6c gene therapy performs in naturally aged dogs. CEO Dr Eric Leire explains why the findings matter, why plasmid DNA has emerged as the preferred veterinary delivery route, how the data are accelerating discussions with animal health companies and why progress in dogs could have wider implications for Genflow’s human sarcopenia programme. Key Moments 00:09 – SLAB-VET delivers an important milestoneDr Leire explains why testing SIRT6c in naturally aged dogs marks a significant step. 00:44 – A centenarian-derived gene moves into real-world ageingEarly signs from older animals provide a new test of Genflow’s longevity approach. 01:05 – Why pDNA is leading the veterinary programmeLower manufacturing costs, scalability and a potentially simpler safety profile underpin the choice. 01:39 – Repeat dosing could strengthen the commercial caseDr Leire highlights practical advantages over viral-vector delivery. 02:11 – Toronto data draw industry attentionScientists, delegates and animal health companies focus on changes in biological age and muscle performance. 02:37 – Naturally aged dogs add translational relevanceThe study differs from laboratory models engineered to accelerate ageing. 03:11 – Results accelerate licensing discussionsGenflow says the presentation has strengthened engagement with potential commercial partners. 03:33 – Partnering rather than building an animal-health businessThe company is targeting licensing, milestone and royalty structures or a potential outright asset sale. 04:19 – Three catalysts investors should watchVeterinary partnering, patent progress and advancement of the human programmes take centre stage. 04:25 – A veterinary deal could bring non-dilutive valueManagement sees partnering as a potential source of capital and external validation for the platform. 04:44 – Europe and Japan patent progressGenflow expects further intellectual-property milestones around its SIRT6 technology. 05:04 – Sarcopenia moves higher up the agendaPositive dog data increase the relevance of Genflow’s work targeting age-related muscle decline in humans. 05:30 – Why dogs may matter more than miceShared environments and lifestyles could make naturally aged dogs a more relevant translational model. 05:50 – Eye and liver programmes add further optionalityGenflow continues to advance additional therapeutic opportunities beyond sarcopenia.

    Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus
  6. 7. Okt.

    Oriole Resources: 32.2Mt Wapouzé Resource Opens a Potential Multi-Decade Revenue Opportunity

    Oriole Resources CEO Martin Rosser explains why the 32.2Mt maiden resource at Wapouzé could support a multi-decade operation — and potentially generate income to help fund ORR’s gold strategy while limiting dilution. Also covered: partner discussions, licensing, Mbe, Bibemi, Eastern CLP and Senala. #ORR #Gold #Mining #Cameroon Key Moments 00:13 – Wapouzé delivers a 32.2Mt maiden resourceMartin puts the scale and quality of the new resource into context. 00:50 – High-grade material with multi-decade potentialWhy the calcium oxide grade, low magnesium content and proposed 400,000tpa operation matter. 01:30 – A route into Cameroon’s cement marketThe potential to displace imported clinker and supply domestic cement production. 02:06 – More than a cement opportunityHigher-grade material could also serve gold processing and chemical-grade markets. 02:39 – Location strengthens the commercial caseWapouzé’s position offers potential access to customers in both Cameroon and neighbouring Chad. 03:22 – Moving from resource towards reservesThe technical, economic and mining work now required to advance the project. 03:50 – Exploitation licence work gathers paceThe PEA and environmental and social impact assessment form key parts of the application. 04:38 – Industry partner discussions move forwardOriole is targeting established domestic players and international groups seeking exposure to the Cameroon and Chad markets. 05:44 – The resource strengthens Oriole’s negotiating positionThe maiden MRE provides substantially more technical information to advance partner discussions. 06:27 – A potentially faster route to productionMartin explains why quarry development could require less capital and move more quickly than a conventional metals mine. 07:17 – Wapouzé could help fund the gold strategyOriole sees potential for royalty-based or other income that could support exploration while reducing dilution. 08:02 – Oriole’s portfolio takes shapeMartin reviews the 1.66Moz Mbe resource, 460,000oz at Bibemi, Wapouzé and Senala. 08:34 – From exploration towards developmentThe company is increasingly focused on defining routes to development and eventual gold production. 09:06 – The next portfolio catalystsBibemi licensing, Mbe economics, Eastern CLP exploration and results from Managem’s US$2m Senala programme are all in focus.

    Oriole Resources: 32.2Mt Wapouzé Resource Opens a Potential Multi-Decade Revenue Opportunity

Info

DirectorsTalk Interviews focus on financial markets and investment opportunities. The site features interviews with company directors, market analysts, and experts, offering insights into companies' performance, industry trends, and market updates. The content includes Q&A sessions, market commentary, and discussions about business developments, often highlighting the viewpoints of executives from publicly traded companies.